|
Pranlukast
Cayman Chemical Item Number 10008319
Description
The cysteinyl leukotrienes (CysLT) LTC4 and LTD4 are potent mediators of asthma and hypersensitivity. They induce bronchoconstriction, increase microvascular permeability, and are vasoconstrictors of coronary arteries. Their biological effects are transduced by a pair of G protein-coupled receptors, CysLT1 and CysLT2.1↗,2↗,3↗ Pranlukast (ONO-1078) is a potent, selective and orally active CysLT1 receptor antagonist.4↗ Sold under the trade name Ultair, it was the first cysteinyl (peptidyl) leukotriene receptor antagonist (LTRA) marketed for the treatment of asthma.5↗ Clinical studies in Japan, Europe, and North America all show that pranlukast significantly attenuates bronchoconstriction in response to a variety of allergen challenges as well as to inhaled LTD4.5↗ Pranlukast binds to the human CysLT1 and CysLT2 receptors with IC50 values of approximately 4-7 nM and 3,600 nM, respectively.1↗,2↗,3↗
Synonyms ONO-1078 Ultair
Formal Name N-[4-oxo-2-(1H-tetrazol-5-yl)-4H-1-benzopyran-8-yl]-4-(4-phenylbutoxy)-benzamide
CAS Number 103177-37-3
Molecular Formula C27H23N5O4
Formula Weight 481.5
Formulation A crystalline solid
Purity ≥98%
λmax 255, 315 nm
Stability 2 years
Storage -20°C
Shipping Room temperature in continental US; may vary elsewhere
SMILES O=C(Nc1cccc2c(=O)cc(oc12)c1[nH]nnn1)c1ccc(OCCCCc2ccccc2)cc1
InCHI Code 1S/C27H23N5O4/c33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18/h1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32)
InCHI Key NBQKINXMPLXUET-UHFFFAOYSA-N |